MAP3K8 and plasma cell myeloma: Accordingly, ablation of Tpl2 in an in vivo myeloma model led to prolonged disease latency via abrogation of the “inflammatory switch” in myeloma–associated monocytes/macrophages within nascent myeloma lesions [133].